Research Agreements (Details)	0 Months Ended	3 Months Ended		6 Months Ended						6 Months Ended		1 Months Ended			0 Months Ended		3 Months Ended		6 Months Ended		1 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended	6 Months Ended		3 Months Ended		6 Months Ended		1 Months Ended							6 Months Ended							1 Months Ended	6 Months Ended					1 Months Ended		6 Months Ended	0 Months Ended			6 Months Ended			6 Months Ended		0 Months Ended		1 Months Ended
	Jun. 11, 2014	Jun. 30, 2014 USD ($)	Jun. 30, 2013 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2013 USD ($)	Jun. 30, 2014 Series A-5 USD ($)	Dec. 31, 2013 Series A-5	Jun. 30, 2014 Series A-6 USD ($)	Dec. 31, 2013 Series A-6	Jun. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Trial Maximum USD ($) item	Jun. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Trial Maximum EUR (€)	Feb. 28, 2013 Clinical Trial Services Agreement Abaloparatide-TD Phase 2 Clinical Trial Nordic Maximum USD ($)	Feb. 28, 2013 Clinical Trial Services Agreement Abaloparatide-TD Phase 2 Clinical Trial Nordic Maximum EUR (€)	Feb. 28, 2013 Clinical Trial Services Agreement Abaloparatide-TD Phase 2 Clinical Trial Nordic Series A-6 Maximum USD ($)	Feb. 28, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Nordic	Jun. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Nordic USD ($)	Jun. 30, 2014 Clinical Trial Services Agreement Pass-through costs USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Pass-through costs USD ($)	Jun. 30, 2014 Clinical Trial Services Agreement Pass-through costs USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Pass-through costs USD ($)	Dec. 31, 2011 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Trial item	Jun. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Trial USD ($)	Jun. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Trial Per patient costs for enrolled patients USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Trial Per patient costs for enrolled patients USD ($)	Jun. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Trial Per patient costs for enrolled patients USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Clinical Trial Per patient costs for enrolled patients USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Abaloparatide-TD Phase 2 Clinical Trial Per patient costs for enrolled patients USD ($)	Jun. 30, 2014 Clinical Trial Services Agreement Abaloparatide-TD Phase 2 Clinical Trial Per patient costs for enrolled patients USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Abaloparatide-TD Phase 2 Clinical Trial Per patient costs for enrolled patients USD ($)	Jun. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Per patient costs for enrolled patients USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Per patient costs for enrolled patients USD ($)	Jun. 30, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Per patient costs for enrolled patients USD ($)	Jun. 30, 2013 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Per patient costs for enrolled patients USD ($)	Mar. 31, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Maximum USD ($)	Mar. 31, 2014 Clinical Trial Services Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Maximum EUR (€)	Mar. 31, 2014 Clinical Trial Services Agreement NB-3 Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Maximum USD ($)	Mar. 31, 2014 Clinical Trial Services Agreement NB-3 Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Maximum EUR (€)	Mar. 31, 2014 Clinical Trial Services Agreement NB-3 Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Series A-6 Maximum USD ($)	Mar. 31, 2014 Clinical Trial Services Agreement NB-3 Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Series A-6 Maximum EUR (€)	Dec. 31, 2011 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Clinical Trial item	Jun. 30, 2014 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Clinical Trial United States item	Jun. 30, 2014 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Clinical Trial United States Maximum USD ($)	Jun. 30, 2014 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Clinical Trial United States Maximum EUR (€)	Jun. 30, 2014 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Clinical Trial India item	Jun. 30, 2014 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Clinical Trial India Maximum USD ($)	Jun. 30, 2014 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Clinical Trial India Maximum EUR (€)	Jun. 30, 2014 Clinical Trial Services Agreement First Amendment Abaloparatide-SC Phase 3 Extension Clinical Study Per patient costs for enrolled patients	Jun. 30, 2012 Clinical Trial Services Agreement Second Amendment Abaloparatide-SC Phase 3 Clinical Trial item	Jun. 30, 2014 Clinical Trial Services Agreement Second Amendment Abaloparatide-SC Phase 3 Clinical Trial USD ($)	Jun. 30, 2014 Clinical Trial Services Agreement Second Amendment Abaloparatide-SC Phase 3 Clinical Trial EUR (€)	Jun. 30, 2014 Clinical Trial Services Agreement Second Amendment Abaloparatide-SC Phase 3 Clinical Trial Maximum USD ($)	Jun. 30, 2014 Clinical Trial Services Agreement Second Amendment Abaloparatide-SC Phase 3 Clinical Trial Maximum EUR (€)	Mar. 31, 2014 Clinical Trial Services Agreement Fourth Amendment Abaloparatide-SC Phase 3 Clinical Trial Nordic USD ($) item	Mar. 31, 2014 Clinical Trial Services Agreement Fourth Amendment Abaloparatide-SC Phase 3 Clinical Trial Nordic Maximum USD ($)	Mar. 31, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Nordic Series A-6 USD ($) item	Jun. 30, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Nordic Series A-6 USD ($)	May 17, 2011 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-SC Phase 3 Clinical Trial Nordic Series A-5 USD ($)	Mar. 29, 2011 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-SC Phase 3 Clinical Trial Nordic Series A-5 EUR (€)	May 17, 2011 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-SC Phase 3 Clinical Trial Nordic Series A-5 Former Operating Company	Jun. 30, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-SC Phase 3 Clinical Trial Nordic Series A-6 Maximum USD ($)	Jun. 30, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-SC Phase 3 Clinical Trial Nordic Series A-6 Maximum EUR (€)	Dec. 31, 2013 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-TD Phase 2 Clinical Trial Nordic Series A-6	Jun. 30, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Series A-6 Maximum USD ($)	Jun. 30, 2014 Clinical Trial Services Agreement Stock Issuance Agreement Abaloparatide-SC Phase 3 Extension Clinical Study Nordic Series A-6 Maximum EUR (€)	Dec. 06, 2013 Clinical Trial Services Agreement Letter of Intent Abaloparatide-SC Phase 3 Extension Clinical Study Nordic USD ($)	Dec. 06, 2013 Clinical Trial Services Agreement Letter of Intent Abaloparatide-SC Phase 3 Extension Clinical Study Nordic EUR (€)	Oct. 31, 2012 Clinical Trial Services Agreement Letter of Intent Abaloparatide-SC Phase 3 Extension Clinical Study Nordic USD ($)	Oct. 31, 2012 Clinical Trial Services Agreement Letter of Intent Abaloparatide-SC Phase 3 Extension Clinical Study Nordic EUR (€)
Research Agreements
Number of countries where study was to be conducted																					10																											12
Number of additional countries where study will be conducted																																								2
Number of additional study sites																																									5			15
Final payments, number of euro-denominated installments										2	2
Final payments, number of U.S dollar-denominated installments										2	2
Amount of euro-denominated payments required over the course of Clinical Trial										$ 56,300,000	€ 41,200,000	$ 4,900,000	€ 3,600,000																					$ 10,300,000	€ 7,500,000	$ 4,100,000	€ 3,000,000					$ 1,600,000	€ 1,200,000		$ 982,531	€ 717,700					$ 5,100,000	€ 3,700,000
Amount of U.S. dollar-denominated payments required over the course of Clinical Trial										3,200,000		300,000																						1,100,000		527,740						143,369			289,663						205,540
Value of shares agreed to be purchased																																																										371,864
Purchase price per share of convertible preferred stock (in dollars per share)						$ 81.42		$ 81.42																																																	$ 8.142
Additional term provided for standard-of-care treatment															18 months																																																		18 months	18 months
Dividend declared (in shares)																																																							186,847	186,847						32,215
Stock dividends declared																																																								29
Number of shares issued						0	6,443	0	496,111																																														186,847	186,847
Payments owed to be changed from the right to receive stock to the right to receive cash payment, if an IPO occurs prior to May 31, 2014																																																							4,300,000
Number of equal monthly installments for cash payments																																																							10
Amount of equal monthly installments for cash payments																																																								430,000
Shares sold	6,500,000																																																								64,430
Proceeds from issuance of shares																																																									525,154
Number of shares exchanged in the Merger																																																											6,443
Aggregate value of quarterly stock dividends, payable in shares														2,900,000																								4,100,000	3,000,000																					50,400,000	36,800,000		10,300,000	7,500,000
Aggregate U.S. dollar value of quarterly stock dividends, payable in shares																																						527,740																									800,000
Number of shares due to the counter party																																																														32,215
Number of shares due to the counter party after conversion of stock																																																														141,294
Amount reflected in accrued expenses and other current liabilities resulting from services payable in cash																2,700,000						11,400,000
Amount of initial payments for Euro-denominated installments																																																																	300,000	222,573	1,100,000	806,468
Maximum aggregate amount of additional payments																																																						5,000,000
Amount of additional performance incentive payable to every specified patient																																																					500,000
Number of patients to whom additional performance incentive is payable																																																					50
Period for which research and development expense is recognized																									20 months			9 months				9 months															19 months
Research and development expense		10,618,000	16,240,000	20,335,000	33,527,000												200,000	900,000	500,000	2,000,000			2,400,000	8,800,000	6,900,000	17,900,000	1,700,000		3,400,000	2,900,000	800,000	5,400,000	1,300,000
Reduction in amount of euro-denominated payments required over the course of clinical study																																																	$ 16,347	€ 11,941